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Conclusions: CrCl reduction after PCI is infrequent in patients with normal baseline
renal function. A modest decrease in CrCl, even after adjusting for other variables, is
associated with significant increases in mortality, bleeding complications and a longer
length of hospitalization. The association with intra-aortic balloon pump use suggests an
embolic mechanism which warrants further investigation.
1062-43 Preprocedure Hyperglycemia Is Stongly Assoicated 
With Restenosis After Coronary Intervention in 
Diabetics
Arvind K. Sharma, Joseph Lindsay, Daniel A. Canos, Ellen Pinnow, Sue Apple, Giacomo 
Ruotolo, Mohan Nandalur, Mevan Wijetunga, Howard Cooper, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background:Restenosis rate after percutaneous coronary intervention (PCI) in diabetic
pts is at least twice that of nondiabetics. We explored potential relationships between res-
tenosis and metabolic factors in diabetics. Methods:Fasting blood samples were
obtained from 162 diabetics (98 men, mean age 62.8±10.7) immediately prior to PCI and
analyzed for insulin, glucose, and hemoglobin A1c (A1c). Insulin resistance (IR) was cal-
culated from the HOMA formula. All pts had successful PCI. Baseline clinical, procedural
and follow-up information was recorded. The primary end point was target vessel revas-
cularization (TVR) rate by 9 months. Results:The insulin level was increased in virtually
all pts(mean 21.0±15.2 µU/ml). No association between TVR and insulin levels or calcu-
lated IR was identified. Only blood glucose level was significantly associated with TVR
(p<0.035).This effect was independent of A1c levels (Figure).The 9-month death plus
nonfatal infarction rate was low (4.2%). No association with the independent variables
could be shown. Conclusion:These data do not support a role for either fasting insulin
level or calculated IR in restenosis. Glucose levels >135 mg/dl were associated with high
TVR rates regardless of A1c levels. The metabolic milieu at the time of the PCI may influ-
ence restenosis.
1062-44 Hypothermia, but Not N-Acetylcysteine or Fenoldopam, 
Prevents Experimental Contrast-Induced Nephropathy
Michael W. Dae, Dong W. Gao, Carol A. Stillson, Gregg W. Stone, Philip C. Ursell, 
University of California at San Francisco, San Francisco, CA, Cardiovascular Research 
Foundation, New York, NY
Background: Contrast-induced nephropathy (CIN) is common after angiographic proce-
dures in high-risk patients. Other than hydration, there is no effective treatment to prevent
CIN. We tested the hypothesis that hypothermia would protect the kidneys from CIN.
Methods: We studied a total of 29 rabbits: controls 39°C, pretreatment with N-Acetylcys-
teine 39°C (NAC, 120 mg/kg over 1 hour, then 11 mg/kg/hr x 4 hours), Fenoldopam 39°C
(0.05 µg/kg/hr x 4 hours), and hypothermia (32°C; 35°C). Hypothermia was induced
using an esophageal heat exchange catheter (Radiant Medical, Inc). Core temperature
was measured in the descending aorta. Rabbits were cooled to target temperature prior
to contrast injection, maintained for 3 hours, then rewarmed. NAC was infused starting 2
hours before contrast injection (Fenoldopam 1 hr before). Iopromide (Ultravist,10.0 g I/kg)
was injected via femoral vein. Serum creatinine (Cr, mg/dl) was measured at baseline,
24, and 48 hours post injection. Kidneys were removed at 48 hours for histology.
Results: Cr results are shown in the table. Significant increases in Cr and extensive
tubular necrosis occurred in controls, NAC, and Fenoldopam, but not in the hypothermic
animals.
Conclusions: Hypothermia started prior to contrast injection provided complete protec-
tion of the kidneys in this experimental model of CIN, and proved superior to NAC and
Fenoldopam. These results suggest that hypothermia may provide a new and effective
strategy for prevention of CIN in high-risk patients. 
1062-45 Prevention of Contrast-Agent-Induced Nephropathy in 
Patients Undergoing a Coronary Procedure by Ascorbic 
Acid
Konstantinos S. Spargias, Elias Alexopoulos, Stamatis Kyrzopoulos, Panagiotis Iakovis, 
Athanassios Manginas, Vassilios Voudris, Gregory Pavlides, Demetrios Kremastinos, 
Dennis V. Cokkinos, Onassis Heart Centre, Athens, Greece
Background: Contrast agents can cause a reduction in renal function that may be due to
generation of reactive oxygen species. There is some evidence suggesting that the
administration of the antioxidant acetylcysteine prevents this renal impairment. The
action of other antioxidant agents, such as ascorbic acid, has not been investigated.
Methods: We conducted a randomized, double-blind, placebo-controlled, prospective
study of ascorbic acid in 231 patients who underwent coronary angiography or interven-
tion and had a serum creatinine concentration > 1.2 mg/dl. Ascorbic acid (3gr at least 2
hours before the procedure, and 2 gr in the night and the morning after the procedure) or
placebo was administered orally. An acute contrast-agent-induced reduction in renal
function was defined as an at least 0.5 mg/dl or a 25% increase in the baseline serum
creatinine concentration measured 2-5 days after the procedure.
Results: Eleven of the 118 patients (9.3%) in the ascorbic acid group, and 23 of the 113
patients (20.4%) in the placebo group achieved the study end-point (p=0.02, relative risk
0.38, 95% confidence interval 0.17 to 0.85). The mean serum creatinine concentration
increased significantly in the placebo group [1.36 (SD:0.50) to 1.50 (0.54) mg/dl,
p<0.001], but not in the ascorbic acid group [1.46 (0.52) to 1.52 (0.64) mg/dl, p=0.20].
The mean increase in the serum creatinine concentration in the placebo group was
greater than that in the ascorbic acid group [0.14 (0.30) vs. 0.06 (0.35) mg/dl, p=0.001].
Conclusion: Prophylactic oral administration of ascorbic acid may protect against con-
trast-agent-induced nephropathy in high-risk patients undergoing a coronary procedure.
1062-46 Preventive Effects of Rosiglitazone on Restenosis After 
Coronary Stent Implantation in Patients With Type 2 
Diabetes Mellitus
Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Sung-Hee Choi, Soo-Kyung Kim, Bong-
Soo Cha, Yonsei University College of Medicine, Seoul, South Korea
Background: After coronary stenting, the restenosis rate is known to be higher in DM
than non-DM patients due to excessive intimal hyperplasia. We investigated the efficacy
of rosiglitazone for preventing restenosis after coronary stenting in diabetic patients.
Methods : We conducted a prospective case-controlled trial involving 95 diabetic
patients (control n=48, rosiglitazone (4 mg per day) group n=47) undergoing coronary
stenting. Serum glucose level and cholesterol were tried to be optimized using additional
hypoglycemic agents and statins. An angiographic follow-up was performed at six
months. Results: A follow-up angiography was performed in 83 patients including 45
patients with 55 lesions in control group (m:f = 31:11, age 59.9±9.3 years), and 38
patients with 51 lesions in the rosiglitazone group (m:f=24:18, age 60.9±9.3 years). The
baseline clinical profile and blood chemistry between two groups were not different.
Baseline angiographic data of control and rosiglitazone group were as following : refer-
ence diameter 3.15±0.49 vs. 3.16±0.49 mm (p=NS), minimal lumen diameter (MLD)
0.65±0.41 vs. 0.83±0.57 mm (p=NS), diameter stenosis (DS) 79.4±12.8 % vs. 74.4±15.8
%, lesion length 16.48±5.16 vs. 19.02±6.09 mm (p<0.05). There was no difference in
MLD or acute gain after coronary stenting between the two groups. The follow-up angiog-
raphy showed a significantly lower binary restenosis rate in the rosiglitazone group than
the control group (17.6% vs. 38.2%, P = 0.03). The follow-up DS (24.2 ± 23.2% vs. 42.9
± 32.2%, P = 0.001) and loss index (0.49±0.41 vs. 0.27±0.30, p=0.008) were also lower
in the rosiglitazone group. Major adverse cardiac events occurred less frequently in the
rosiglitazone group (10.5% vs 20%, p=0.244) at 6 months, although it was not statistically
significant. The serum glucose, insulin, lipid concentrations were similar at 6- month fol-
low-up in the both groups. Conclusions: Rosiglitazone effectively reduced restenosis in
diabetic patients after coronary stenting. This effect is probably related to pleotrophic
property of rosiglitazone rather than its hypoglycemic effect.
1062-47 Marked Improvements in In-Hospital Outcomes 
Following Contemporary Percutaneous Coronary 
Intervention in Patients With Diabetes
David O. Williams, Alice K. Jacobs, Helen A. Vlachos, Katherine M. Detre, Rhode Island 
Hospital, Providence, RI
Background: Presence of diabetes mellitus (DM) has been associated with adverse
results among patients (pts) treated by percutaneous coronary intervention (PCI).
Methods: We sought to determine whether advances in PCI over time have impacted in-
hospital clinical outcomes of pts with DM. Pts with DM were identified and analyzed in the
1985-86 PTCA Registry (n=325) and in the 1997-2001 enrollment waves of the NHLBI
Dynamic Registry (n=622).
Results: Pts in the Dynamic Registry were older (64.1 vs. 60.7 years, p<0.001), more
often had history of hypertension (80.0% vs. 61.8%, p<0.001), severe concomitant non-
cardiac disease (45.5% vs. 9.5%, p<0.001), and lower LV ejection fractions (50.4% vs.
57.8%, p<0.001). No differences were observed in gender, prior CABG, history of CHF,
number of vessels diseased or mean number of lesions. AMI was more often an indica-
tion for PCI in the Dynamic Registry (27.7% vs. 7.4%, p<0.001) and procedures were
more often emergent or urgent. In the Dynamic Registry, fewer lesions were attempted
per pt (1.4 vs. 1.7, p<0.001) and lesion location was less often the LAD (36.8% vs.
45.3%, p<0.05). Stents were used in 87.5% of Dynamic Registry pts and in no 1985-86
pts. Angiographic success was higher in the Dynamic Registry (94.8% vs. 78.1%,
p<0.001) and abrupt closure (0.9% vs. 2.2%, p<0.05), death (1.9% vs. 4.3%, p<0.05), MI
(1.0% vs. 7.4%, P<0.001) and in-hospital CABG (0.8% vs. 6.2%, p<0.001) were less
common.
Conclusions: Although pts with DM having contemporary PCI were older and had more
Cr Baseline Cr 24 hrs Cr 48 hrs
Control, 39°C (n=6) 1.1±0.2 3.9±1.8* 5.8±3.3*
NAC (n=6) 0.8±0.1 2.3±0.9* 4.3±1.6*
Fenoldopam (n=6) 1.0±0.2 2.8±1.0* 5.3±1.3*
Hypo-35°C (n=5) 0.8±0.1 1.1±0.2**# 0.9±0.2#
Hypo-32°C (n=6) 1.2±0.2 1.1±0.3# 1.0±0.3#
*P<0.01 vs baseline
**P=0.05 vs baseline
#P<0.01 vs
Control,NAC,
Fenoldopam
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serious cardiac and non-cardiac disease, their in-hospital clinical outcomes were consid-
erably better than those pts treated earlier. Greater selectivity in lesion revascularization
coupled with technical advances such as stents may contribute to these more favorable
results in this important pt population with CAD.
1062-48 Blood Glucose Level Predicts Severity of Renal and 
Myocardial Injury in Diabetic Patients Undergoing 
Coronary Interventions
Bryan J. Robertson, Joseph A. Gascho, Steven M. Ettinger, Ian C. Gilchrist, Mark Kozak, 
Charles E. Chambers, Patrick H. McNulty, Penn State- Milton S. Hershey Medical Center, 
Hershey, PA
Background: Patients with diabetes mellitus (DM) having percutaneous coronary inter-
ventions (PCI) are at increased risk for both contrast nephropathy and adverse cardiac
events. Theoretical considerations suggest glucose itself may mediate these risks by
synergizing with radiocontrast to initiate oxidative injury.
Methods: To test the hypothesis that pre-PCI serum glucose levels predict renal and
myocardial injury, we analyzed 558 DM patients who underwent PCI at our institution
from 1998 to 2002. We stratified 165 patients who had both a 48-hour peak serum creat-
inine (a marker of renal microvascular injury) and a 24-hour peak serum creatine phos-
phokinase (a marker of myocardial microvascular injury) into low glucose (<200 mg/dl,
n=88) and high glucose (>200 mg/dl, n=77) groups. The groups were similar in age (64+/
-14 versus (vs.) 65+/-12 years), gender (43% vs. 46% female), procedure (all balloon +/-
stent), contrast volume received (217+/-100 vs. 239+/-87 ml, p=0.16), and contrast type.
Results: Despite a trend toward better renal function in the high glucose group (creati-
nine=1.2+/-0.9 vs. 1.4+/-1.1 mg/dl, p=0.14), high glucose patients exhibited a greater
post-PCI rise in creatinine (0.26+/-0.5 vs. 0.17+/-0.5 mg/dl, p=0.15), a greater percent
increase in creatinine (21+/-39% vs. 12+/-27%, p=0.03), and a 5-fold higher chance of
suffering a >50% increase in creatinine (10% vs. 2%). High glucose patients were twice
as likely to have a non-Q wave myocardial infarction (40% vs. 21%) with a higher abso-
lute post-PCI CPK than low glucose patients (2666+/-390 vs. 1908+/-368 IU, p=0.07).
Even among patients without a non-Q wave myocardial infarction, high glucose patients
exhibited significantly greater post-PCI peak CPK’s (223+/-220 vs. 153+/-117 IU,
p=0.02).
Conclusion: Almost one-half of DM patients at our institution have blood glucoses >200
mg/dl at the time of PCI. Compared to matched patients with glucose <200 mg/dl, ele-
vated glucose patients exhibit a greater degree of both renal and myocardial injury after
PCI. Because correcting hyperglycemia prior to PCI is easy and inexpensive, the hypoth-
esis that euglycemia might improve outcomes from PCI in DM should be tested in a clini-
cal trial.
1062-49 Clinical Outcome Following Percutaneous Coronary 
Intervention in Patients With End-Stage Renal Disease
Mamoru Toyofuku, Yasuhiko Hayashi, Michinori Imazu, Yoshiko Masaoka, Hironori Ueda, 
Tadamichi Sakuma, Yuji Muraoka, Hidekazu Hirao, Takenori Okada, Shinji Mito, Ken 
Ishibashi, Kentaro Miura, Tsuchiya General Hospital, Hiroshima, Japan
Cardiovascular(CV) mortality remains high in end-stage renal disease(ESRD) with coro-
nary artery disease. Current developments of percutaneous coronary intervention (PCI)
devices may improve immediate and long term outcome in these high risk patients but
data were limited. Methods From the total of 1010 patients (age<80, 1500 lesions) who
underwent PCI between April 2000 to July 2002, we identified 100 patients (179 lesions)
with chronic dialysis. These were followed for one-year and compared with 100 age and
sex matched patients selected from control group. Results: In ESRD, lesions were more
extended (the number of diseased vessels: 1.9 vs. 1.7, p=0.01) and calcification was
more common (52% vs. 10%, p<0.001). The characteristics of procedure in ESRF were
more frequent use of rotablator (43% vs. 8%, p<0.001) and high utilization rate of stent
(74% vs. 73%, NS). In ESRF, the rates of procedural success (97% vs. 98% NS) and
one-year target lesion revascularization(TLR) (26% vs. 21%, NS) were similar in both
groups. However, in hospital death (5% vs. 1% p=0.001), new lesion development which
needed revascularization (27% vs. 10%, p=0.005), and one-year CV mortality rate (15%
vs. 2%, p<0.001) were markedly high in ESRD. In ESRD, factors concerning one-year CV
mortality were elevated CRP, diabetes, and AMI. Multivariate analysis showed elevated
CRP was the strongest predictor of CV mortality (RR2.7 per tertile of CRP, 95%CI 1.3-
5.8). CONCLUSION: The utilization of current PCI devices, such as stent and rotablator,
contributed to high procedural successful rate and acceptable restenosis rate in ESRD.
However, ESRF showed progressive development of new coronary artery lesions and
high mortality rate in short and long term. Elevated CRP was related to the poor progno-
sis.
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1063-51 Clopidogrel Resistance Is Associated With Cytochrome 
3A Polymorphism
Jung W. Suh, Seoul National University Hospital, Seoul, South Korea
Background: Recent reports indicate that there are clopidogrel non-responders in the
population. Clopidogrel is transformed to its active metabolite by cytochrome P450 3A. A
single-nucleotide polymorphism (A6986G) in the CYP3A5 gene distinguishes an expres-
sor (A) and a reduced-expressor (G) allele and largely predicts CYP3A5 content in liver
and intestine. We postulate that clopidogrel resistance is associated with CYP3A5 poly-
morphism and investigated the relationship. Methods & Results: Patients (n=175) treated
clopidogrel after stenting were investigated. We analyzed single nucleotide polymor-
phism (A6986G) by polymerase chain reaction (PCR) and restriction enzyme digestion.
The genotype frequency was GG (97): AG (62): AA (16). The frequency of the GG geno-
type was 0.56, lower than that of Caucasians. But in nine patients who have developed
major adverse cardiac events within 3 months, the frequency of GG genotype was
0.89(GG: AG:AA=8:1:0). In the multivariate analysis including clinical and angiographic
characteristics, the GG genotype was a significant predictor of early MACE(MI, stroke,
SAT, death) after stenting (p=0.044). Follow up angiography was done at 6month
(n=140). The GG genotype was not significant predictor of in-stent restenosis. In order to
confirm the functional significance of the CYP3A5 polymorphism, we administered clopi-
dogrel (300mg loading and 75mg qd for 7days) to nine normal volunteers of AA, AG, GG
genotype (n=3 for each type). We performed platelet aggregation test (baseline, 4hr, 24hr
and 7days). There were tendency that platelet aggregation was more inhibited in the AA
type than non-AA type (AG+GG).Conclusion: CYP 3A5 polymorphism seems to be asso-
ciated with pharmacokinetics of clopidogrel and is associated with the early major
adverse cardiac event after coronary stenting . This polymorphism may explain the indi-
vidual difference in clopidogrel resistance.
1063-52 Lack of Efficacy of Clopidogrel Pretreatment in the 
Prevention of Myocardial Damage After Elective Stent 
Implantation
Dirk J. van der Heijden, Iris C. Westendorp, Robert K. Riezebos, Ferdinand Kiemeneij, 
Ton Slagboom, Ron L. van der Wieken, Gert-Jan Laarman, Onze Lieve Vrouwe 
Gasthuis, Amsterdam, The Netherlands
Background - Non-randomized studies on pre-treatment with ADP receptor blockers of
patients undergoing urgent stent implantation have suggested a reduction in myocardial
damage with pretreatment. In elective stenting the effect of pre-treatment with clopidogrel
has not yet been studied.
Methods - In a randomised trial 3 days pre-treatment with clopidogrel was compared to
standard post-procedural treatment, in addition to aspirin and heparin, in 203 patients
with stable coronary syndromes undergoing elective stentplacement. Primary endpoint
was a rise in troponin I and CK-MB 6 or 24 hours after stentplacement. Secondary end-
points were clinical endpoints at 24 hours, 1 month and 6 months after PCI and a com-
posite endpoint.
Results - No difference was found between not pre-treated and pre-treated patients in
the occurrence of elevation of CK-MB (respectively 6 (6.3%) vs. 7 (7.4%); p=0.78) or
troponin I (respectively 42 (43.3%) vs. 48 (51.1%); p=0.31). Adjustment for baseline val-
ues and possible confounding factors did not change these findings. The composite end-
point occurred in 47 (46.1%) of the not pre-treated patients and in 55 (54.5%) of the pre-
treated patients (p=0.26). Follow up showed no significant difference between the treat-
ment groups in the clinical endpoints.
Conclusion - In this randomized study no beneficial effect of pre-treatment with clopi-
dogrel on the elevation of troponin I, CK-MB or adverse cardiac events after 1 and 6
months could be demonstrated. Therefore we conclude that among patients with stable
coronary syndromes in whom stenting of coronary arteries is planned pre-treatment is
not mandatory in reducing early myocardial damage.
1063-53 A Rational Approach to Coronary Stenting Prior to 
Noncardiac Surgery
Mark Awar, Amit Mittal, Bipin Ravindran, Amit Kalra, Tarang Patel, Nicholas Ruggiero, 
Baback Adibi, Alexander Kaplan, Steven Silver, Paul Walinsky, Howard Weitz, David 
Fischman, Michael Savage, Thomas Jefferson University Hospital, Philadelphia, PA
Background: The optimal timing of noncardiac surgery (NCS) after coronary stenting
has not been determined. Earlier studies showed a high mortality rate due to stent throm-
bosis and perioperative hemorrhage when NCS is performed within two weeks of PCI.
Based on the known temporal course of stent reendothelization we devised the following
four step strategy: 1) A four-week course of clopidogrel post PCI 2) Deferral of elective
NCS for 5 to 12 weeks post stenting 3) Discontinuation of clopidogrel for a minimum of 5
days prior to surgery and 4) Use of heparin coated stents in high-risk patients. The pur-
pose of this study was to validate the clinical efficacy of this therapeutic strategy.
Methods: Forty six patients with significant CAD underwent PCI prior to planned NCS.
NCS was performed at a median of 48 (range: 39-89) days post PCI. All NCS were done
under general anesthesia and consisted of the following: Abdominal 35%, orthopedic
24%, vascular 15%, carotid 13%, thoracic 9% and miscellaneous 4%. In- hospital out-
